Streck, Sysmex sign agreement, 5/16
May 2016—Streck and Sysmex Inostics, a subsidiary of Sysmex Corp., have announced that Sysmex has signed a worldwide supply and distribution agreement with Streck.
Tuesday, November 10, 2026, 1:00 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Samuel Caughron, MD, FCAP, Chief Strategy Officer, MAWD Pathology, Medical Director of Laboratory, AdventHealth Kansas City, Medical Director of Laboratory, Labcorp, President, Member & Director, Pathology Ventures, LLC
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, November 18, 2026, 12:00 PM-1 PM ET
Join leading pathology experts, Savitri Krishnamurthy, MD, and Marilyn Bui, MD, PhD, for a webinar exploring potential challenges in HER2 IHC testing for breast cancer, emerging evidence supporting digital and computational pathology as assistive tools for pathologists in HER2 IHC assessment, and practical considerations for real-world implementation and adoption.
Webinar presenters Savitri Krishnamurthy, MD, Professor of Pathology, Department of Anatomical Pathology The University of Texas MD Anderson Cancer Center, Houston, Texas, and Marilyn Bui, MD, PhD, Surgical Pathologist and Cytopathologist Member and Professor, Departments of Pathology, Machine Learning, and Translational Pathology, Scientific Director, Analytic Microscopy Core Chair, Women in Oncology Executive Board Moffitt Cancer Center, Tampa, Florida
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speakers are being compensated for their presentations. The program is not CME accredited and may not be used for CME credit.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers
Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
May 2016—Streck and Sysmex Inostics, a subsidiary of Sysmex Corp., have announced that Sysmex has signed a worldwide supply and distribution agreement with Streck.
May 2016—Enzo Life Sciences now offers the Cytag TotalCGH Labeling Kit for CGH+SNP arrays. Array-based comparative genomic hybridization is a well-established method for investigating copy number variations and is used to detect a variety of genomic gains and losses from duplications and deletions, unbalanced translocations, and aneuploidies.
May 2016—The Spooner Girls Foundation, which funds research toward treatments and a cure for mitochondrial complex I deficiency, along with the University of California Irvine School of Medicine and Population Diagnostics, announced a collaborative research initiative focused on the NUBPL gene.
May 2016—Rheonix has completed development and testing of a microfluidic system and assay to simultaneously detect host anti-HIV antibodies and viral RNA in a single specimen of saliva or blood.
May 2016—Accumen, a San Diego-based health care services company, has announced the acquisition of Ann Arbor, Mich.-based Chi Solutions, a clinical laboratory consulting and management firm.
May 2016—The ALK-RET-ROS1 targeted formalin-fixed, paraffin-embedded RNA Fusion Reference Standards from Horizon are a highly characterized, biologically relevant quality control material to assess the performance of next-generation sequencing, RT-PCR, and RT-qPCR assays aimed at detecting gene fusions.
May 2016—Roche announced the launch of the Discovery Yellow Kit, an alkaline phosphatase-based detection chemistry for tissue diagnostics that produces a unique, transparent yellow signal that is not washed away during alcohol dehydration.
May 2016—Qiagen will collaborate with 10x Genomics to develop and promote comprehensive solutions for next-generation sequencing, single-cell biology, and bioinformatics.
May 2016—Bio-Rad Laboratories announced CE IVD marking for its QX200 Droplet Digital PCR System. The technology, which partitions a DNA or RNA sample into 20,000 droplets and amplifies targeted sequences within each droplet, allows scientists to precisely detect and quantify low concentrations of target DNA and RNA sequences.
April 2016—Euroimmun, headquartered in Luebeck, Germany, has developed a system of comprehensive tests available for the serological detection and differentiation of Zika virus infections.